Readers: What follows is part 4 of a series intended to defog the strange misunderstanding that is cholesterol in modern medicine. Part 1 explains a mistake that birthed the Lipid Hypothesis, part 2 explains how we failed in measuring success, part 3 walks through the data, which reveals a yawning gap between doctor- and patient-centered science, and today’s part 4 is about how good, smart people were fooled.
Next week part 5, the final piece, will focus on what you can do about it. Enjoy!
Research Translation is 100% reader-supported. To help me keep going, please consider becoming a paid subscriber.
In 1995, I was a second-year medical student.
Between lectures I would slip into the library, where the latest journals and newspapers were laid out like a daily briefing from the front lines of science. One afternoon I came across the WOSCOPS trial—the Scottish study being hailed as the first successful use of statins for primary prevention.
I read the paper. Then the coverage of the paper. Then I thought back to the lectures from that very morning, where professors spoke about it with something close to excitement.
This was a moment, I thought.
A real one. The kind you imagine when you decide to go into medicine. A major problem, yielding to science. I remember feeling proud—not just of the result, but of the field. It felt like progress you could wear, a new stitch in the white coat.
I was wrong.
What I did not know then—and still stings—is that the investigators had acknowledged in an earlier, largely unnoticed paper, that the WOSCOPS trial participants were all chosen because “to a greater or lesser degree” they already had heart disease.
In other words, WOSCOPS was a trial of secondary prevention, selecting participants at much higher risk of heart problems, and thus far more likely to see any benefits. But that is not how it was presented. Not in the journal. Not in the headlines. Not in the lecture hall.
Which means the cholesterol story did not, as I believed, begin with a clean proof. It began with a tilted foundation.
After WOSCOPS dozens more statin trials were published, with over 160,000 additional participants. Today, only by sifting tables in an online supplementary appendix can we see who those participants actually were. But cold-case forensics occasionally pay off.
Across statin trials, it turns out, participants had cardiac risk levels 5-10 times higher than today’s average statin taker.
And that was just the first tilt.
The trials themselves were also designed to favor success: run-in phases that dropped anyone with side effects, composite outcomes driven by minor events, slanted analyses, and data that even today remain hidden from the public. What emerged was not a neutral picture. It was a carefully shaped message.
So why did doctors and scientists believe it?
Data sculpted by profiteers is not special or uncommon. And it is not enough to sustain decades of conviction among intelligent people. For that, you need something else.
In 1799, three accomplished physicians drained nearly a gallon of blood from George Washington, then watched him die. They were neither incompetent nor careless. They were simply true believers in ‘humoral imbalance’, and acted in accordance with the best training and most accepted theories of their time.
The Lipid Hypothesis is among the most accepted theories of our time.
Better yet, lowering cholesterol feels like progress. Patients take the drug, numbers improve, and harms are invisible. For doctors, their experience confirms their belief. Belief then shapes interpretation. The cycle continues.
Over time, the idea doesn’t stay in journals—it enters the culture. We joke about ‘artery-clogging’ foods, pass the butter with a wink, and speak of cholesterol as if it is the known and principal cause of heart disease. At that point it is no longer a hypothesis. It is something closer to an article of faith.
And something else begins to shift.
The role of the physician-scientist—rooted in dispassion, inquiry, and the disciplined logic of scientific method—quietly gives way to something more comfortable. We stop asking whether a hypothesis is true, and begin assuming it must be. We stop demanding outcomes that matter, and begin accepting ones that are easy to measure.
Modern trials reflect this perfectly.
In the most recent example the entire claim of benefit came from nonfatal MIs and unnecessary stents. Death was unchanged. Disability was unchanged.
Which means the researchers, the journal, and its readers all counted the study as a success—but the people being treated did not. Cholesterol medicine is now a field almost fully disconnected from the lives it purports to improve.
This is how ideologic gumption and experiential delusion operate: not by replacing science, but by quietly reshaping how it is interpreted.
In 1995, I sat in a library and thought I was watching medicine get something right.
But it was something else entirely: a narrative taking shape. One that would be repeated, refined, and rarely questioned. What began as a narrow finding in the sickest patients became a broad prescription for the healthy—not because the evidence was clear, but because the mindset was already in place to receive it.
That is how this story began. And why it has been so difficult to upend.
Stay tuned for part 5 next week, a shorty on what to do about the cholesterol problem.
